Cargando…
Hyperpolarized (13)C MRI: Path to Clinical Translation in Oncology
This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) (13)C magnetic resonance imaging’s (MRI’s) widespread clinical use, and provide recommendations for overcoming them. Since the pub...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260457/ https://www.ncbi.nlm.nih.gov/pubmed/30472500 http://dx.doi.org/10.1016/j.neo.2018.09.006 |
_version_ | 1783374796766052352 |
---|---|
author | Kurhanewicz, John Vigneron, Daniel B. Ardenkjaer-Larsen, Jan Henrik Bankson, James A. Brindle, Kevin Cunningham, Charles H. Gallagher, Ferdia A. Keshari, Kayvan R. Kjaer, Andreas Laustsen, Christoffer Mankoff, David A. Merritt, Matthew E. Nelson, Sarah J. Pauly, John M. Lee, Philips Ronen, Sabrina Tyler, Damian J. Rajan, Sunder S. Spielman, Daniel M. Wald, Lawrence Zhang, Xiaoliang Malloy, Craig R. Rizi, Rahim |
author_facet | Kurhanewicz, John Vigneron, Daniel B. Ardenkjaer-Larsen, Jan Henrik Bankson, James A. Brindle, Kevin Cunningham, Charles H. Gallagher, Ferdia A. Keshari, Kayvan R. Kjaer, Andreas Laustsen, Christoffer Mankoff, David A. Merritt, Matthew E. Nelson, Sarah J. Pauly, John M. Lee, Philips Ronen, Sabrina Tyler, Damian J. Rajan, Sunder S. Spielman, Daniel M. Wald, Lawrence Zhang, Xiaoliang Malloy, Craig R. Rizi, Rahim |
author_sort | Kurhanewicz, John |
collection | PubMed |
description | This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) (13)C magnetic resonance imaging’s (MRI’s) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized (13)C MRI in 2011, preclinical studies involving [1-(13)C]pyruvate as well a number of other (13)C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-(13)C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP (13)C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind. |
format | Online Article Text |
id | pubmed-6260457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62604572018-12-06 Hyperpolarized (13)C MRI: Path to Clinical Translation in Oncology Kurhanewicz, John Vigneron, Daniel B. Ardenkjaer-Larsen, Jan Henrik Bankson, James A. Brindle, Kevin Cunningham, Charles H. Gallagher, Ferdia A. Keshari, Kayvan R. Kjaer, Andreas Laustsen, Christoffer Mankoff, David A. Merritt, Matthew E. Nelson, Sarah J. Pauly, John M. Lee, Philips Ronen, Sabrina Tyler, Damian J. Rajan, Sunder S. Spielman, Daniel M. Wald, Lawrence Zhang, Xiaoliang Malloy, Craig R. Rizi, Rahim Neoplasia Review article This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) (13)C magnetic resonance imaging’s (MRI’s) widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized (13)C MRI in 2011, preclinical studies involving [1-(13)C]pyruvate as well a number of other (13)C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic information. A dose-ranging study of HP [1-(13)C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP (13)C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind. Neoplasia Press 2018-11-23 /pmc/articles/PMC6260457/ /pubmed/30472500 http://dx.doi.org/10.1016/j.neo.2018.09.006 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review article Kurhanewicz, John Vigneron, Daniel B. Ardenkjaer-Larsen, Jan Henrik Bankson, James A. Brindle, Kevin Cunningham, Charles H. Gallagher, Ferdia A. Keshari, Kayvan R. Kjaer, Andreas Laustsen, Christoffer Mankoff, David A. Merritt, Matthew E. Nelson, Sarah J. Pauly, John M. Lee, Philips Ronen, Sabrina Tyler, Damian J. Rajan, Sunder S. Spielman, Daniel M. Wald, Lawrence Zhang, Xiaoliang Malloy, Craig R. Rizi, Rahim Hyperpolarized (13)C MRI: Path to Clinical Translation in Oncology |
title | Hyperpolarized (13)C MRI: Path to Clinical Translation in Oncology |
title_full | Hyperpolarized (13)C MRI: Path to Clinical Translation in Oncology |
title_fullStr | Hyperpolarized (13)C MRI: Path to Clinical Translation in Oncology |
title_full_unstemmed | Hyperpolarized (13)C MRI: Path to Clinical Translation in Oncology |
title_short | Hyperpolarized (13)C MRI: Path to Clinical Translation in Oncology |
title_sort | hyperpolarized (13)c mri: path to clinical translation in oncology |
topic | Review article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260457/ https://www.ncbi.nlm.nih.gov/pubmed/30472500 http://dx.doi.org/10.1016/j.neo.2018.09.006 |
work_keys_str_mv | AT kurhanewiczjohn hyperpolarized13cmripathtoclinicaltranslationinoncology AT vignerondanielb hyperpolarized13cmripathtoclinicaltranslationinoncology AT ardenkjaerlarsenjanhenrik hyperpolarized13cmripathtoclinicaltranslationinoncology AT banksonjamesa hyperpolarized13cmripathtoclinicaltranslationinoncology AT brindlekevin hyperpolarized13cmripathtoclinicaltranslationinoncology AT cunninghamcharlesh hyperpolarized13cmripathtoclinicaltranslationinoncology AT gallagherferdiaa hyperpolarized13cmripathtoclinicaltranslationinoncology AT kesharikayvanr hyperpolarized13cmripathtoclinicaltranslationinoncology AT kjaerandreas hyperpolarized13cmripathtoclinicaltranslationinoncology AT laustsenchristoffer hyperpolarized13cmripathtoclinicaltranslationinoncology AT mankoffdavida hyperpolarized13cmripathtoclinicaltranslationinoncology AT merrittmatthewe hyperpolarized13cmripathtoclinicaltranslationinoncology AT nelsonsarahj hyperpolarized13cmripathtoclinicaltranslationinoncology AT paulyjohnm hyperpolarized13cmripathtoclinicaltranslationinoncology AT leephilips hyperpolarized13cmripathtoclinicaltranslationinoncology AT ronensabrina hyperpolarized13cmripathtoclinicaltranslationinoncology AT tylerdamianj hyperpolarized13cmripathtoclinicaltranslationinoncology AT rajansunders hyperpolarized13cmripathtoclinicaltranslationinoncology AT spielmandanielm hyperpolarized13cmripathtoclinicaltranslationinoncology AT waldlawrence hyperpolarized13cmripathtoclinicaltranslationinoncology AT zhangxiaoliang hyperpolarized13cmripathtoclinicaltranslationinoncology AT malloycraigr hyperpolarized13cmripathtoclinicaltranslationinoncology AT rizirahim hyperpolarized13cmripathtoclinicaltranslationinoncology |